Harbin Pharmaceutical Group (600664.SH): Sodium sulfate receives approval for marketing application of chemical active pharmaceutical ingredient

Harbin Pharmaceutical Group (600664.SH) announced that recently, its affiliated company Harbin Pharmaceutical Group Bioengineering Co., Ltd. received the "Approval Notice for Marketing Application of Chemical Active Pharmaceutical Ingredient" for sodium sulfate issued by the National Medical Products Administration. Sodium sulfate is one of the active pharmaceutical ingredients of Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Oral Concentrated Solution, exerting its efficacy through an osmotic cathartic mechanism. With the approval notice for the marketing application of the chemical active pharmaceutical ingredient obtained this time, its registration status has changed to "A", indicating that this active pharmaceutical ingredient has met the relevant national technical standards for drug review, and will subsequently be mainly used for the application and production of the company's associated formulation, Magnesium Sulfate, Sodium Sulfate and Potassium Sulfate Oral Concentrated Solution.